Woodline Partners LP Prelude Therapeutics Inc Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $131,520 - $229,920	-48,000 Reduced 19.35%	200,000 $618,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $1.1 Million - $2.01 Million	248,000 New	248,000 $1.12 Million
Q4 2020 Feb 16, 2021	SELL	$28.81 - $88.94 $5.17 Million - $16 Million	-179,361 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$26.2 - $30.13 $4.7 Million - $5.4 Million	179,361 New	179,361 $5.4 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.2M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.